FDA Adverse Event Malfunction Summary report: N

GELSOFT

MDR report key: 8734304 · Received June 26, 2019

Report

Report Number
9612515-2019-00012
Event Type
Malfunction
Date Received
June 26, 2019
Date of Event
May 25, 2019
Report Date
June 25, 2019
Manufacturer
VASCUTEK LTD
Product Code
MAL
UDI-DI
05037881110493
PMA / PMN Number
P890045/S1
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). A REVIEW OF MANUFACTURING AND QC RECORDS CONFIRMED THAT THE DEVICE WAS MANUFACTURED TO SPECIFICATION. WITHOUT THE RETURN OF THE GRAFT FOR ANALYSIS VASCUTEK LTD ARE UNABLE TO DETERMINE A ROOT CAUSE FOR THIS EVENT. HOWEVER FROM A REVIEW OF CLINICAL PAPERS AND THE DEVICE IFU IT HAS BEEN NOTED THAT DILATATION IS A KNOWN AND EXPECTED COMPLICATION OF THIS TYPE OF PROCEDURE DUE TO THE KNITTED STRUCTURE OF THE GRAFT. THE PERCENTAGE OF DILATATION VARIES SIGNIFICANTLY THROUGHOUT LITERATURE. IN THE LAST FIVE YEARS FROM 2014 TO 2019 VASCUTEK LTD HAS RECEIVED A TOTAL OF 8 COMPLAINTS, FOR KNITTED GRAFTS WHERE DILATATION OF THE GRAFT HAS BEEN REPORTED AS AN ISSUE. SALES FOR THIS PERIOD AND GRAFT TYPE IS (B)(4) UNITS. THIS GIVES A VERY LOW INCIDENT RATE OF (B)(4). AS DILATATION OF KNITTED GRAFTS IS INHERENT AND EXPECTED THERE IS NO COMMON INDUSTRY INCIDENT RATE FOR COMPARISON. ON THIS BASIS VASCUTEK NOW CONSIDERS THIS COMPLAINT CLOSED. HOWEVER THIS ISSUE WILL BE TRACKED AND TRENDED AS PART OF THE ROUTINE COMPLAINTS MONITORING AND REPORTING PROCESS. IF AN ADVERSE TREND DEVELOPS ACTIONS WILL BE TAKEN AT THAT TIME.

Description of Event or Problem · 1

THE EVENT, WHICH OCCURRED IN (B)(6) WAS REPORTED TO VASCUTEK LTD AS FOLLOWS: THE PATIENT RECEIVED BIFURCATED GRAFT. DURING CT FOLLOW UP THE PHYSICIAN OBSERVED AN INCREASE OF THE DIAMETER OF THE MAIN GRAFT BODY TO 31MM.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
530427 GELSOFT GELSOFT BIFURCATE MAL VASCUTEK LTD 17713202 2012 05037881110493

Patients

Seq Age Sex Outcome Treatment
1